CMBA
IPXL

C.M. Bidwell & Associates’s Impax Laboratories, Inc. IPXL Stock Holding History

C.M. Bidwell & Associates’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,405
Closed -$160K – 276
2015
Q1 		$160K Buy
+3,405
New +$135K 0.04% 179

Other funds holding IPXL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HP
Hound Partners New York $799M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Pennant Capital Management Summit, New Jersey $212M AUM 19.37% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AG
Aravt Global New York $11.3M AUM 3.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

C.M. Bidwell & Associates's IPXL Position: Q2 2015 in Review

C.M. Bidwell & Associates sold out of Impax Laboratories, Inc. (IPXL) in Q2 2015, closing a stake of 3,405 shares — an estimated $160K sold.

C.M. Bidwell & Associates first reported a position in IPXL in Q1 2015 and held it in 1 quarter. The position peaked at $160K in Q1 2015. 197 funds tracked by Wall St. Rank hold IPXL as of Q2 2015.

  • C.M. Bidwell & Associates reported no remaining Impax Laboratories, Inc. position as of Q2 2015 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 3,405 Impax Laboratories, Inc. shares in Q2 2015, an estimated $160K.
  • C.M. Bidwell & Associates first reported a position in Impax Laboratories, Inc. in Q1 2015 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Impax Laboratories, Inc. position peaked at $160K in Q1 2015.
  • 197 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2015.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2015, filed 21 Aug 2015.